Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 33189178

Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet
Publication date
2020 Nov 14
First author
Grosicki S

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2021 May 1;397(10285):1620-1621. doi: 10.1016/S0140-6736(21)00274-9.
    note
    Source null
    related pmid
    33933200
    relationship
    Comment in
  2. citation
    Lancet. 2021 May 1;397(10285):1621-1623. doi: 10.1016/S0140-6736(21)00271-3.
    note
    Source null
    related pmid
    33933201
    relationship
    Comment in
  3. citation
    Lancet. 2021 May 1;397(10285):1621. doi: 10.1016/S0140-6736(21)00270-1.
    note
    Source null
    related pmid
    33933202
    relationship
    Comment in

Authors and identifiers

  1. name
    Grosicki S
    type
    Author
  2. name
    Simonova M
    type
    Author
  3. name
    Spicka I
    type
    Author
  4. name
    Pour L
    type
    Author
  5. name
    Kriachok I
    type
    Author
  6. name
    Gavriatopoulou M
    type
    Author
  7. name
    Pylypenko H
    type
    Author
  8. name
    Auner HW
    type
    Author
  9. name
    Leleu X
    type
    Author
  10. name
    Doronin V
    type
    Author
  11. name
    Usenko G
    type
    Author
  12. name
    Bahlis NJ
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Grosicki S
    type
    Author
  2. name
    Simonova M
    type
    Author
  3. name
    Spicka I
    type
    Author
  4. name
    Pour L
    type
    Author
  5. name
    Kriachok I
    type
    Author
  6. name
    Gavriatopoulou M
    type
    Author
  7. name
    Pylypenko H
    type
    Author
  8. name
    Auner HW
    type
    Author
  9. name
    Leleu X
    type
    Author
  10. name
    Doronin V
    type
    Author
  11. name
    Usenko G
    type
    Author
  12. name
    Bahlis NJ
    type
    Author
bibliography ids
  1. nci-bib-db675c4c7602435f202c7942
book metadata
content sha256
2bede35be07f13fa677e05db469ab401bd614f7edd9ec059e108ab0e13270617
document type
citation
dois
  1. 10.1016/S0140-6736(20)32292-3
electronic publication date
display
Source null
precision
missing
year
Source null
evidence scope
bibliographic_metadata_only
id
pubmed:33189178
immutable id
pubmed:33189178@2bede35be07f13fa677e05db469ab401bd614f7edd9ec059e108ab0e13270617
journal
abbreviation
Lancet
issn electronic
1474-547X
issn print
0140-6736
issue
10262
name
Lancet (London, England)
nlm unique id
2985213R
pages
1563-1573
volume
396
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2021 May 1;397(10285):1620-1621. doi: 10.1016/S0140-6736(21)00274-9.
    note
    Source null
    related pmid
    33933200
    relationship
    Comment in
  2. citation
    Lancet. 2021 May 1;397(10285):1621-1623. doi: 10.1016/S0140-6736(21)00271-3.
    note
    Source null
    related pmid
    33933201
    relationship
    Comment in
  3. citation
    Lancet. 2021 May 1;397(10285):1621. doi: 10.1016/S0140-6736(21)00270-1.
    note
    Source null
    related pmid
    33933202
    relationship
    Comment in
outcomes validated
false
pmid
33189178
provenance
batch id
9bca82d1bba2b27adc79
provider
NCBI PubMed ESummary
record sha256
fdc072d6a0f50395de7ee7a551eac8176e129c63dbbaa5e68271d1b9ea3c9f4c
response sha256
c8a4853c65a45038af15f5ade3970763bfa121cf5c68bafcc52c3a06860d0211
retrieved at
2026-09-09T23:47:56.131551+00:00
publication date
display
2020 Nov 14
precision
day
year
2020
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/33189178/
title
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.

Preserved source evidence · Not medical advice